The first such vaccine, Provenge, was approved in the U.S. in 2010 to treat prostate cancer.
首个此类疫苗Provenge于2010年在美国获得批准，该疫苗用于治疗前列腺癌。
英语百科
Sipuleucel-T
Sipuleucel-T (APC8015, trade name Provenge), manufactured by Dendreon Corporation, is a cell-based cancer immunotherapy for prostate cancer (CaP). It is a personalized treatment that works by programming each patient's immune system to seek out cancer and attack it as if it were foreign.